N A Sandiford1, J R Hutt2, D O Kendoff3, P A Mitchell2, M Citak4, L Granger2. 1. The Complex Arthroplasty Unit, St George's Hospital, London, UK. nemsandiford@gmail.com. 2. The Complex Arthroplasty Unit, St George's Hospital, London, UK. 3. Chefarzt Zentrum für Orthopädie und Unfallchirurgie, Berlin, Germany. 4. Helios EndoKlinik, Hamburg, Germany.
Abstract
INTRODUCTION: Prosthetic joint infection (PJI) remains one of the major challenges facing orthopaedic surgeons. There is a paucity of evidence on non-operative management of PJI. We present the results of prolonged antibiotic suppression therapy (PSAT) in PJI from a single centre. METHODS: A retrospective study was performed. Twenty-six patients were included. Two patients were excluded due to the lack of follow-up data. Failure was defined as admission for sepsis from the joint or amputation. RESULTS: Average age was 72 years (range 35-93). Mean Charlson co-morbidity index was 4.3. Mean follow-up was 3.2 years (range 1.3-5.7). Staphylococcal species were isolated in 11 cases (44%) (MRSA 1, MSSA 5, Staph. epidermidis 4 and Staph Pasteuri 1). Other bacteria included E. Coli (2), Streptococci spp. (3), Propionebacterium acnes (1) and Pseudomonas aeruginosa (1). Four cases were polymicrobial infection (16%), and no organisms were identified in two cases (8%). Candida albicans was identified in one case. All cases of bacterial infection were treated with prolonged oral doxycycline or amoxicillin. Twenty patients (80%) received 6 weeks of intravenous antibiotics prior to commencing prolonged oral antibiotics. Two patients experienced persistent symptoms and required amputation (both TKA). Two patients experienced sepsis but were treated successfully with IV antibiotics alone. The success rate of PSAT was 84% (21/25) successful at an average 3.2-year follow-up. DISCUSSION AND CONCLUSION: Prolonged suppressive antibiotic therapy is a viable option for the management of PJI with a low incidence of complications.
INTRODUCTION: Prosthetic joint infection (PJI) remains one of the major challenges facing orthopaedic surgeons. There is a paucity of evidence on non-operative management of PJI. We present the results of prolonged antibiotic suppression therapy (PSAT) in PJI from a single centre. METHODS: A retrospective study was performed. Twenty-six patients were included. Two patients were excluded due to the lack of follow-up data. Failure was defined as admission for sepsis from the joint or amputation. RESULTS: Average age was 72 years (range 35-93). Mean Charlson co-morbidity index was 4.3. Mean follow-up was 3.2 years (range 1.3-5.7). Staphylococcal species were isolated in 11 cases (44%) (MRSA 1, MSSA 5, Staph. epidermidis 4 and Staph Pasteuri 1). Other bacteria included E. Coli (2), Streptococci spp. (3), Propionebacterium acnes (1) and Pseudomonas aeruginosa (1). Four cases were polymicrobial infection (16%), and no organisms were identified in two cases (8%). Candida albicans was identified in one case. All cases of bacterial infection were treated with prolonged oral doxycycline or amoxicillin. Twenty patients (80%) received 6 weeks of intravenous antibiotics prior to commencing prolonged oral antibiotics. Two patients experienced persistent symptoms and required amputation (both TKA). Two patients experienced sepsis but were treated successfully with IV antibiotics alone. The success rate of PSAT was 84% (21/25) successful at an average 3.2-year follow-up. DISCUSSION AND CONCLUSION: Prolonged suppressive antibiotic therapy is a viable option for the management of PJI with a low incidence of complications.
Authors: Marcelo B P Siqueira; Anas Saleh; Alison K Klika; Colin O'Rourke; Steven Schmitt; Carlos A Higuera; Wael K Barsoum Journal: J Bone Joint Surg Am Date: 2015-08-05 Impact factor: 5.284
Authors: I Byren; P Bejon; B L Atkins; B Angus; S Masters; P McLardy-Smith; R Gundle; A Berendt Journal: J Antimicrob Chemother Date: 2009-03-31 Impact factor: 5.790
Authors: Miguel Cámara; William Green; Cait E MacPhee; Paulina D Rakowska; Rasmita Raval; Mark C Richardson; Joanne Slater-Jefferies; Katerina Steventon; Jeremy S Webb Journal: NPJ Biofilms Microbiomes Date: 2022-05-26 Impact factor: 8.462
Authors: Robert Nißler; Oliver Bader; Maria Dohmen; Sebastian G Walter; Christine Noll; Gabriele Selvaggio; Uwe Groß; Sebastian Kruss Journal: Nat Commun Date: 2020-11-25 Impact factor: 14.919
Authors: Enrico Maria Zardi; Paolo Persichetti; Alessio Palumbo; Edoardo Franceschetti; Francesco Franceschi Journal: Int J Environ Res Public Health Date: 2021-08-31 Impact factor: 3.390